SEC62 and head and neck squamous cell carcinoma: Taken together, we have shown in our study that SEC62 represents an independent prognostic biomarker in HNSCC patients treated with primary chemoradiotherapy with SEC62 overexpression correlating with a significantly shorter overall survival and advanced lymph node metastases.